story of the week
Pathological Response and Survival in TNBC After Neoadjuvant Carboplatin + Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin Plus Docetaxel
Clin. Cancer Res 2018 Sep 26;[EPub Ahead of Print], P Sharma, S López-Tarruella, JA García-Saenz, QJ Khan, HL Gómez, A Prat, F Moreno, Y Jerez-Gilarranz, A Barnadas, AC Picornell, M Del Monte-Millán, M González-Rivera, T Massarrah, B Pelaez-Lorenzo, MI Palomero, R González Del Val, J Cortés, H Fuentes-Rivera, DB Morales, I Márquez-Rodas, CM Perou, C Lehn, YY Wang, JR Klemp, JV Mammen, JL Wagner, AL Amin, AP O'Dea, J Heldstab, RA Jensen, BF Kimler, AK Godwin, M MartínFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.